Wound Chamber Delivery of Platelet Lysate For The Treatment Of Corneal Injuries
Jennifer McDaniel1, Andrew Holt1, Anthony Johnson1, Elof Eriksson2, Gina Griffith1.
1USAISR, Fort Sam Houston, TX, USA, 2Harvard Medical School, Boston, MA, USA.
Strategies to address corneal surface defects are insufficient to successfully resolve damage caused by injury and/or disease. To address this issue, we have developed an ocular wound chamber (OWC) that allows for the continuous delivery of therapeutics. The aim of this study was to test human platelet lysate (hPL) as a therapeutic for corneal epithelial defects when used with the OWC. Corneal injuries were created in anesthetized hairless guinea pigs by demarcating the central cornea with a 4 mm punch biopsy followed by debridement of the cornea. An OWC was placed over injured eyes and animals randomly grouped followed by injection of 20% hPL, 100% hPL, or vehicle into the chamber. Eyes were assessed at 0, 24, 48, and 72h using intraocular pressure (IOP), optical coherence tomography (OCT), and fluorescein imaging. Whole globes were histologically processed and H&E stained. No significant differences in IOP were recorded as a result of corneal wounding, chamber placement, and/or therapeutic application. OCT images demonstrated increased corneal swelling at 48h (P=0.031) and 72h (P=0.006) in the vehicle group compared to 20% hPL. Fluorescein imaging showed increased wound closure in 20% hPL animals at 24h compared to 100% hPL (P=0.0004) and vehicle (P<0.0001). By 48h, 20% and 100% hPL animals exhibited increased corneal re-epithelialization (P<0.0001, P=0.0126) compared to vehicle. H&E staining revealed cellular infiltrate in the stroma of all groups. Results from this study demonstrate hPL delivery via the OWC improves corneal re-epithelialization compared to vehicle alone. This study supports the expanded usage of the OWC in combination with hPL to manage a variety of corneal surface injuries, diseases and/or periocular conditions.
Back to 2019 Posters